.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EA01_Imatinib.Imatinib_1 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EA01_Imatinib.Imatinib_1| name: | Imatinib_1 |
| ATC code: | L01EA01_1 | route: | oral |
| n-compartments | 1 |
Imatinib is a tyrosine kinase inhibitor used as standard of care for chronic myeloid leukemia and gastrointestinal stromal tumors.
Alternative pharmacokinetic model in healthy volunteers after single oral administration.
Menon-Andersen, D, et al., & Barrett, JS (2009). Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer chemotherapy and pharmacology 63(2) 229–238. DOI:10.1007/s00280-008-0730-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18398615
Widmer, N, et al., & Buclin, T (2006). Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. British journal of clinical pharmacology 62(1) 97–112. DOI:10.1111/j.1365-2125.2006.02719.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16842382
Golabchifar, AA, et al., & Rouini, MR (2014). Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. Cancer chemotherapy and pharmacology 74(1) 85–93. DOI:10.1007/s00280-014-2473-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24817601